Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters (iPregnostic)

November 3, 2026 updated by: iPremom

Prospective, Observational, Multicentre Study to Confirm the Performance of Molecular Screening for Early Detection of Preeclampsia

Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions.

Current screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (<41%) in compliance with NICE and ACOG guidelines.

Recent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening.

The current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This multicentre, prospective observational study aims to validate the MaiRa Preeclampsia Test, a molecular screening tool for predicting early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) in the first and second trimesters of pregnancy. The study will evaluate its diagnostic accuracy, including sensitivity, specificity, predictive values, and area under the curve (AUC).

Study Design:

Duration: 40 months

  • Recruitment and Sample Collection: 28 months
  • Sample Analysis: 32 months
  • Follow-Up: 8 months
  • Statistical Analysis and Publication: 6 months Participants: 7,473 pregnant women from 12 tertiary hospitals in Spain.

Visits:

  • Visit 1 (T1): 9-14 weeks' gestation (first blood sample)
  • Visit 2 (T2): 15-26 weeks' gestation (second blood sample)
  • Visit 3 (T3): ≥27 weeks' gestation (third blood sample)

Blood samples will be analyzed using the MaiRa Preeclampsia Test, with results correlated against obstetric outcomes as the gold standard. Data will be documented in an electronic Case Report Form (eCRF). Quality assurance will be maintained via continuous data monitoring and verification.

Study Type

Observational

Enrollment (Estimated)

7473

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alicante
      • Alicante, Alicante, Spain, 03010
        • Hospital General Universitario Dr. Balmis
    • Barcelona
      • Barcelona, Barcelona, Spain, 08025
        • Hospital de la Santa Creu i Sant Pau
    • Castellón
      • Vinaròs, Castellón, Spain, 12500
        • Hospital Comarcal de Vinaròs
    • Cádiz
      • Cadiz, Cádiz, Spain, 11009
        • Hospital Universitario Puerta del Mar
    • La Coruña
      • A Coruña, La Coruña, Spain, 15006
        • Hospital Universitario A Coruña
    • Madrid
      • Torrejón de Ardoz, Madrid, Spain, 28850
        • Hospital Universitario de Torrejón
    • Murcia
      • El Palmar, Murcia, Spain, 30120
        • Hospital Clínico Universitario Virgen de la Arrixaca
    • Santa Cruz de Tenerife
      • San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain, 38320
        • Hospital Universitario de Canarias
    • Valencia
      • Manises, Valencia, Spain, 46940
        • Hospital de Manises
      • Valencia, Valencia, Spain, 46017
        • Hospital Universitario Doctor Peset
      • Valencia, Valencia, Spain, 46026
        • Hospital Universitario y Politécnico La Fe

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Pregnant patients aged 18 years or older, recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.

Description

Inclusion Criteria:

  • Signed informed consent approved by the Ethics Committee.
  • Women ≥18 years of age at consent.
  • Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation.

Exclusion Criteria:

  • Active neoplasm.
  • History of organ or bone marrow transplantation.
  • Maternal transfusion within 8 weeks before sample collection.
  • Evidence of early pregnancy loss at consent.
  • Severe, uncontrolled infections.
  • Other investigator-assessed risks that could compromise participation or data quality.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pregnant patients aged 18 years or older

Pregnant patients aged 18 years or older recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.

Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validation of the MaiRa Preeclampsia Test for first-trimester screening (9-14 weeks) of EOPE
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validation of second-trimester screening (15-26 weeks) for EOPE
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
Validation of second-trimester screening (15-26 weeks) for LOPE
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exploratory outcome: Validation of first-trimester screening (9-14 weeks) for LOPE
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
Exploratory outcome: Validation of first and second trimester screening for other pregnancy complications
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Other pregnancy complications such as preterm labour, intrauterine growth restriction, gestational diabetes and placenta previa among others.

Sensitivity, specificity, accuracy, F1-score, positive/negative predictive values, false discovery rate, AUC.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
Exploratory outcome: Molecular characterization of cfRNA and other biomarkers across gestation
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

DNA/RNA/proteins/metabolites associated with gestational age and clinical outcomes.

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.
Exploratory outcome: Identification of candidate biomarkers in maternal blood for therapeutic interventions
Time Frame: From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Molecular characterization (DNA/RNA/proteins/metabolites).

From the date of enrollment (minimum 9 weeks) until the end of pregnancy (maximum 43 weeks), assessed up to 34 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Carlos Simón, MD, PhD, Carlos Simon Foundation
  • Principal Investigator: Tamara Garrido, PhD, iPremom

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 2, 2024

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

November 25, 2024

First Submitted That Met QC Criteria

November 28, 2024

First Posted (Actual)

December 4, 2024

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IPR-IPR-TG-24-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.